Blood clotting is initiated by the two-subunit enzyme consisting of the plasma protease, factor VIIa (the catalytic subunit), bound to the integral membrane protein, tissue factor (the regulatory subunit). Molecular dynamics simulations have predicted that certain residues in the tissue factor ectodomain interact with phosphatidylserine headgroups to ensure optimal positioning of the tissue factor/factor VIIa complex relative to its membrane-bound protein substrates, factors IX and X. In this study, we individually mutated to alanine all the putative phosphatidylserine-interactive residues in the tissue factor ectodomain and measured their effects on tissue factor cofactor function (activation of factors IX and X by tissue factor/factor VIIa, and clotting of plasma). Some tissue factor mutants exhibited decreased activity in all three assays, with the most profound defects observed from mutations in or near the flexible loop from Lys159 to Gly164. The decreased activity of all of these tissue factor mutants could be partially or completely overcome by increasing the phosphatidylserine content of tissue factor-liposomes. Additionally, yeast surface display was used to screen a random library of tissue factor mutants for enhanced factor VIIa binding. Surprisingly, mutations at a single amino acid (Lys165) predominated, with the Lys165→Glu mutant exhibiting a 3-fold enhancement in factor VIIa binding affinity. Our studies reveal the functional contributions of residues in the C-terminal half of the tissue factor ectodomain that are implicated in interacting with phosphatidylserine headgroups to enhance tissue factor cofactor activity, possibly by allosterically modulating the conformation of the adjacent substrate-binding exosite region of tissue factor.
References
[1]
Morrissey JH, Mutch NJ (2006) Tissue factor structure and function. In: Colman RW, Marder VJ, Clowes AW, George JN, Goldhaber SZ, editors. Hemostasis and Thrombosis: Basic Principles and Clinical Practice. Philadelphia: Lippincott Williams & Wilkins. 91–106.
[2]
Persson E, Olsen OH (2011) Allosteric activation of coagulation factor VIIa. Front Biosci 17: 3156–3163. doi: 10.2741/3903
[3]
Kirchhofer D, Lipari MT, Moran P, Eigenbrot C, Kelley RF (2000) The tissue factor region that interacts with substrates factor IX and factor X. Biochemistry. 39: 7380–7387. doi: 10.1021/bi000182+
[4]
Kirchhofer D, Eigenbrot C, Lipari MT, Moran P, Peek M, et al. (2001) The tissue factor region that interacts with factor Xa in the activation of factor VII. Biochemistry 40: 675–682. doi: 10.1021/bi002013v
[5]
Carlsson K, Freskg？rd PO, Persson E, Carlsson U, Svensson M (2003) Probing the interface between factor Xa and tissue factor in the quaternary complex tissue factor-factor VIIa-factor Xa-tissue factor pathway inhibitor. Eur J Biochem 270: 2576–2582. doi: 10.1046/j.1432-1033.2003.03625.x
[6]
Manithody C, Yang L, Rezaie AR (2007) Identification of a basic region on tissue factor that interacts with the first epidermal growth factor-like domain of factor X. Biochemistry. 46: 3193–3199. doi: 10.1021/bi6025193
[7]
Morrissey JH, Neuenschwander PF, Huang Q, McCallum CD, Su B, et al. (1997) Factor VIIa-tissue factor: functional importance of protein-membrane interactions. Thromb Haemost 78: 112–116.
[8]
McCallum CD, Hapak RC, Neuenschwander PF, Morrissey JH, Johnson AE (1996) The location of the active site of blood coagulation factor VIIa above the membrane surface and its reorientation upon association with tissue factor. A fluorescence energy transfer study. J Biol Chem 271: 28168–28175. doi: 10.1074/jbc.271.45.28168
[9]
McCallum CD, Su B, Neuenschwander PF, Morrissey JH, Johnson AE (1997) Tissue factor positions and maintains the factor VIIa active site far above the membrane surface even in the absence of the factor VIIa Gla domain. A fluorescence resonance energy transfer study. J Biol Chem 272: 30160–30166. doi: 10.1074/jbc.272.48.30160
[10]
Ohkubo YZ, Morrissey JH, Tajkhorshid E (2010) Dynamical view of membrane binding and complex formation of human factor VIIa and tissue factor. J Thromb Haemost 8: 1044–1053. doi: 10.1111/j.1538-7836.2010.03826.x
[11]
Waters EK, Yegneswaran S, Morrissey JH (2006) Raising the active site of factor VIIa above the membrane surface reduces its procoagulant activity but not factor VII autoactivation. J Biol Chem 281: 26062–26068. doi: 10.1074/jbc.m604915200
[12]
Neuenschwander PF, Bianco-Fisher E, Rezaie AR, Morrissey JH (1995) Phosphatidylethanolamine augments factor VIIa-tissue factor activity: enhancement of sensitivity to phosphatidylserine. Biochemistry 34: 13988–13993. doi: 10.1021/bi00043a004
[13]
Smith SA, Morrissey JH (2004) Rapid and efficient incorporation of tissue factor into liposomes. J Thromb Haemost 2: 1155–1162. doi: 10.1111/j.1538-7836.2004.00772.x
[14]
Neuenschwander PF, Morrissey JH (1994) Roles of the membrane-interactive regions of factor VIIa and tissue factor. The factor VIIa Gla domain is dispensable for binding to tissue factor but important for activation of factor X. J Biol Chem 269: 8007–8013.
[15]
Fiore MM, Neuenschwander PF, Morrissey JH (1994) The biochemical basis for the apparent defect of soluble mutant tissue factor in enhancing the proteolytic activities of factor VIIa. J Biol Chem 269: 143–149.
[16]
Sturzebecher J, Kopetzki E, Bode W, Hopfner KP (1997) Dramatic enhancement of the catalytic activity of coagulation factor IXa by alcohols. FEBS Lett 412: 295–300. doi: 10.1016/s0014-5793(97)00811-9
[17]
Waters EK, Morrissey JH (2006) Restoring full biological activity to the isolated ectodomain of an integral membrane protein. Biochemistry 45: 3769–3774. doi: 10.1021/bi052600m
[18]
Starwalt SE, Masteller EL, Bluestone JA, Kranz DM (2003) Directed evolution of a single-chain class II MHC product by yeast display. Protein Eng 16: 147–156. doi: 10.1093/proeng/gzg018
[19]
Morrissey JH, Fair DS, Edgington TS (1988) Monoclonal antibody analysis of purified and cell-associated tissue factor. Thromb Res 52: 247–261. doi: 10.1016/0049-3848(88)90084-9
[20]
Boder ET, Wittrup KD (1997) Yeast surface display for screening combinatorial polypeptide libraries. Nat Biotechnol 15: 553–557. doi: 10.1038/nbt0697-553
[21]
Rezaie AR, Fiore MM, Neuenschwander PF, Esmon CT, Morrissey JH (1992) Expression and purification of a soluble tissue factor fusion protein with an epitope for an unusual calcium-dependent antibody. Protein Expression Purif 3: 453–460. doi: 10.1016/1046-5928(92)90062-2
[22]
Kelley RF, Costas KE, O’Connell MP, Lazarus RA (1995) Analysis of the factor VIIa binding site on human tissue factor: Effects of tissue factor mutations on the kinetics and thermodynamics of binding. Biochemistry 34: 10383–10392. doi: 10.1021/bi00033a009
[23]
O’Shannessy DJ, Brigham-Burke M, Soneson KK, Hensley P, Brooks I (1993) Determination of rate and equilibrium binding constants for macromolecular interactions using surface plasmon resonance: use of nonlinear least squares analysis methods. Anal Biochem 212: 457–468. doi: 10.1006/abio.1993.1355
[24]
Ruf W, Miles DJ, Rehemtulla A, Edgington TS (1992) Tissue factor residues 157–167 are required for efficient proteolytic activation of factor X and factor VII. J Biol Chem 267: 22206–22210.
[25]
Zwaal RFA, Comfurius P, Bevers EM (1998) Lipid-protein interactions in blood coagulation. Biochim Biophys Acta 1376: 433–453. doi: 10.1016/s0304-4157(98)00018-5
[26]
Morrissey JH, Macik BG, Neuenschwander PF, Comp PC (1993) Quantitation of activated factor VII levels in plasma using a tissue factor mutant selectively deficient in promoting factor VII activation. Blood 81: 734–744.
[27]
Banner DW, D’Arcy A, Chène C, Winkler FK, Guha A, et al. (1996) The crystal structure of the complex of blood coagulation factor VIIa with soluble tissue factor. Nature 380: 41–46. doi: 10.1038/380041a0
[28]
Muller YA, Ultsch MH, de Vos AM (1996) The crystal structure of the extracellular domain of human tissue factor refined to 1.7 ？ resolution. J Mol Biol 256: 144–159. doi: 10.1006/jmbi.1996.0073
[29]
Huang Q, Neuenschwander PF, Rezaie AR, Morrissey JH (1996) Substrate recognition by tissue factor-factor VIIa. Evidence for interaction of residues Lys165 and Lys166 of tissue factor with the 4-carboxyglutamate-rich domain of factor X. J Biol Chem 271: 21752–21757. doi: 10.1074/jbc.271.36.21752
[30]
Roy S, Hass PE, Bourell JH, Henzel WJ, Vehar GA (1991) Lysine residues 165 and 166 are essential for the cofactor function of tissue factor. J Biol Chem 266: 22063–22066.
[31]
Ruf W, Miles DJ, Rehemtulla A, Edgington TS (1992) Cofactor residues lysine 165 and 166 are critical for protein substrate recognition by the tissue factor-factor VIIa protease complex. J Biol Chem 267: 6375–6381.
[32]
Rehemtulla A, Ruf W, Miles DJ, Edgington TS (1992) The third Trp-Lys-Ser (WKS) tripeptide motif in Tissue Factor is associated with a function site. Biochem J 282 (Pt 3): 737–740.
[33]
Harlos K, Martin DMA, O’Brien DP, Jones EY, Stuart DI, et al. (1994) Crystal structure of the extracellular region of human tissue factor. Nature 370: 662–666. doi: 10.1038/370662a0
